Jump to main content
Jump to site search

Issue 30, 2012
Previous Article Next Article

Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy

Author affiliations

Abstract

Photodynamic therapy (PDT) has shown promise as an effective treatment modality for cancers and other localized diseases, such as age-related macular degeneration and actinic keratosis. PDT relies on light, photosensitizer and oxygen as elements in its mechanism of action. BODIPY photosensitizers that have been under extensive study over the past decade have been demonstrated as a new class of photosensitizers. In this review, we attempt to summarize the decade-long study of BODIPY-based photosensitizers. We provide an overview of the superior photophysical properties possessed by BODIPY-based agents and the various synthetic strategies employed that have led to improved and selective and/or targeted photosensitizers.

Graphical abstract: Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 09 Jul 2012, accepted on 06 Sep 2012 and first published on 07 Sep 2012


Article type: Review Article
DOI: 10.1039/C2RA21404K
Citation: RSC Adv., 2012,2, 11169-11183
  •   Request permissions

    Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy

    S. G. Awuah and Y. You, RSC Adv., 2012, 2, 11169
    DOI: 10.1039/C2RA21404K

Search articles by author

Spotlight

Advertisements